# Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

> **NCT04901416** · PHASE1 · COMPLETED · sponsor: **Coeptis Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- AML, Adult Recurrent
- MDS

## Interventions

- **BIOLOGICAL:** DVX201

## Key facts

- **NCT ID:** NCT04901416
- **Lead sponsor:** Coeptis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2023-10-15
- **Final completion:** 2024-06-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901416, "Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04901416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*